Cargando…

Radium-223 and bone metastatic disease: still more to learn

Detalles Bibliográficos
Autor principal:	Sartor, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640878/ https://www.ncbi.nlm.nih.gov/pubmed/37952210 http://dx.doi.org/10.1093/jncics/pkad083

Ejemplares similares

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223
por: Viani, Gustavo
Publicado: (2023)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings
por: Sartor, Oliver, et al.
Publicado: (2021)

Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223
por: Hijab, Adham, et al.
Publicado: (2021)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
por: Takalkar, Amol, et al.
Publicado: (2014)

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
por: George, Daniel J., et al.
Publicado: (2022)

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer
por: Makita, Kenji, et al.
Publicado: (2023)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
por: Harrison, Michael R, et al.
Publicado: (2013)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

Recurrent Extraneural Metastatic Medulloblastoma in an Adult Presenting With a Superscan and Treated With Radium-223
por: Mou, Benjamin, et al.
Publicado: (2023)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy
por: Anderson, Pete M, et al.
Publicado: (2020)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Current approaches to incorporation of radium-223 in clinical practice
por: Parker, Chris, et al.
Publicado: (2018)

Imaging and dosimetry for radium-223: the potential for personalized treatment
por: Flux, Glenn D
Publicado: (2017)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
por: Gayed, Isis, et al.
Publicado: (2018)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

An agent-based model of prostate Cancer bone metastasis progression and response to Radium223
por: Casarin, Stefano, et al.
Publicado: (2020)

Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study
por: Kawahara, Takashi, et al.
Publicado: (2022)

Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation
por: Hosono, Makoto, et al.
Publicado: (2018)

Patient selection and treatment response assessment in radium-223 therapy
por: Kay, M, et al.
Publicado: (2015)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Ocular complications with the use of radium-223: a case series
por: Bloom, Julie R., et al.
Publicado: (2022)

Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients
por: Umeda, Takuro, et al.
Publicado: (2017)

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
por: Nguyen, Nghi C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gdm6gte02avro39s59vb7g7bd7